NCT07198724 2026-04-09
ERADICATE
Dana-Farber Cancer Institute
Phase 1/2 Recruiting
Clinical Trials
15 trialsNCT06382948 2026-04-03
ADELA
MedSIR
Phase 3 Recruiting
NCT06923527 2026-03-27
Circulating Tumor DNA
Yale University
Phase 2 Recruiting
NCT06075953 2026-03-16
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT07395336 2026-02-09
COMBINE-01
European Institute of Oncology
Phase 2 Not yet recruiting
NCT07222215 2026-01-22
CAPELA
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT05826964 2026-01-13
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
Phase 2 Active not recruiting
NCT06691035 2025-12-04
Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Recruiting
NCT06201234 2025-12-01
ELEMENT
GBG Forschungs GmbH
Phase 2 Recruiting
NCT07159451 2025-12-01
POP-ELA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Recruiting
NCT07242352 2025-11-21
ADAPTela
West German Study Group
Phase 3 Not yet recruiting
NCT06062498 2025-10-20
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
Northwestern University
Phase 2 Recruiting
NCT07005882 2025-06-05
HELP
Azienda Ospedaliero-Universitaria Careggi
Phase 2 Not yet recruiting
NCT05982093 2025-05-22
SOLTI-2104
SOLTI Breast Cancer Research Group
Phase 2 Active not recruiting
NCT04797728 2022-10-26
ELIPSE
SOLTI Breast Cancer Research Group
Phase EARLY_PHASE1 Completed